Drug Trial Radar · NCT03024177
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Last checked: Nov 19, 2026Latest source record: May 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Not stated
Primary completion
Apr 2017
Sponsor
- Lead sponsor
- VaxartIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study of vapendavir treatment of laboratory-confirmed and symptomatic HRV infection of the upper respiratory tract in allogeneic and autologous stem cell transplant subjects. The aim of this study is to evaluate the effect of vapendavir on laboratory-confirmed HRV upper-respiratory tract infection in HSCT patients, as measured by viral load changes, worsening of upper respiratory tract infection (URTI) to lower respiratory tract infection (LRTI), duration of clinical symptoms, the occurrence of supplemental oxygen use, duration of viral shedding, hospital admission and duration of hospitalization, incidence of secondary bacterial infection, and mortality rates. Additionally, the safety and tolerability of vapendavir, and the vapendavir plasma levels achieved in the HSCT population, and the profile of viral resistance development will also be assessed.
Conditions
- Rhinovirus
- Upper Respiratory Tract Infection
Interventions
VapendavirDrug
Vapendavir Tablets, 264 mg
Placebo Oral TabletDrug
Vapendavir 264 mg matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Time-weighted average change from baseline to end of treatment visit in HRV viral load (HRV-RNA log10 copies/mL)Time frame: Study Day 1 to end of treatment (Study Day 14)
- Safety: Proportion of treatment-emergent adverse eventsTime frame: Study Day 1 - 90
- Safety: Proportion of treatment-related serious adverse eventsTime frame: Study Day 1 - 90
- Safety: Incidence of treatment-emergent Grade 3 or greater clinical laboratory abnormalitiesTime frame: Study Day 1 - 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.